GRI Bio, Inc. (GRI)

GRI Bio's stock price has experienced a significant decline over the past year. In September 2025, GRI Bio reported six-week lung function data from its Phase 2a study of GRI-0621 in Idiopathic Pulmonary Fibrosis (IPF), indicating no decline in lung function, building upon positive safety and biomarker data. In May 2025, GRI Bio reported its first-quarter 2025 financial results and confirmed its GRI-0621 Phase 2a IPF trial was on track and closed a public offering for aggregate gross proceeds of $5.0 million. GRI Bio has actively participated in investor conferences to highlight its pipeline and investment opportunities.

As a clinical-stage biopharmaceutical company focused on developing novel therapies, GRI Bio, Inc. does not currently have commercialized products. Therefore, there is no discernible demand seasonality for its products or services at this stage of its business.

GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for diseases linked to dysregulated immune responses, including inflammatory, fibrotic, and autoimmune disorders. Their lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T (NKT) cells, in Phase IIa clinical trial for severe fibrotic lung diseases. The company's pipeline also includes GRI-0803, a novel oral agonist of type 2 NKT cells, in preclinical development for autoimmune disorders. Additionally, GRI Bio possesses a proprietary library of over 500 compounds and is developing GRI-0124 and GRI-0729 to balance inflammatory immune responses.

GRI Bio, Inc. primarily focuses its operations and development efforts within the United States. The company's headquarters are located in La Jolla, California.

GRI Bio's brand reputation in the past year appears to be primarily shaped by its clinical development progress and engagement with the investment community. Positive announcements regarding interim data from its Phase 2a study for GRI-0621 in IPF have contributed to its scientific standing. The company's participation in various investor conferences also suggests an active effort to maintain visibility and attract investment. There is no specific information indicating events that have negatively impacted GRI Bio, Inc.'s brand reputation in the past year, beyond the general decline in stock price.

The ownership structure of GRI Bio (GRI) stock is a mix of institutional, insider, and retail investors. Approximately 4.00% to 5.05% of the company's stock is owned by institutional investors, while insiders hold around 22.77% to 84.15%, and retail investors own approximately 11.74% to 72.18%. Major institutional owners include DRW Securities, LLC, Vanguard Group Inc, Geode Capital Management, Llc, Tower Research Capital LLC (TRC), FSMAX - Fidelity Extended Market Index Fund, FCFMX - Fidelity Series Total Market Index Fund, BlackRock, Inc., SBI Securities Co., Ltd., UBS Group AG, and Bank Of America Corp /de/. Joseph E. Payne is noted as the largest individual shareholder, owning 26.35% of the company's shares.